Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWP14012 Tablet A vs Tablet B in Healthy Volunteers
NCT04167267Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the drug concentration-time curve from time 0 to tau at 48 hour and Peak concentration at 48 hour. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04167267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04167267.